General American Investors Co. Inc. trimmed its stake in Pfizer Inc. (NYSE:PFE) by 17.4% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 380,808 shares of the biopharmaceutical company’s stock after selling 80,000 shares during the period. General American Investors Co. Inc.’s holdings in Pfizer were worth $13,595,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other institutional investors also recently added to or reduced their stakes in the business. Shine Investment Advisory Services Inc. bought a new stake in shares of Pfizer in the 2nd quarter valued at about $102,000. Mckinley Capital Management LLC Delaware bought a new stake in shares of Pfizer in the 2nd quarter valued at about $103,000. D. Scott Neal Inc. raised its holdings in shares of Pfizer by 19.3% in the 2nd quarter. D. Scott Neal Inc. now owns 3,112 shares of the biopharmaceutical company’s stock valued at $105,000 after purchasing an additional 504 shares in the last quarter. Herndon Capital Management LLC bought a new stake in shares of Pfizer in the 2nd quarter valued at about $120,000. Finally, Private Vista LLC raised its stake in shares of Pfizer by 2,277.3% during the 2nd quarter. Private Vista LLC now owns 199,317 shares of the biopharmaceutical company’s stock worth $133,000 after acquiring an additional 190,933 shares in the last quarter. 69.79% of the stock is owned by institutional investors.
Several research analysts recently commented on PFE shares. Nord/LB reiterated a “neutral” rating on shares of Pfizer in a research note on Wednesday, December 27th. Zacks Investment Research upgraded shares of Pfizer from a “hold” rating to a “buy” rating and set a $41.00 price objective for the company in a research note on Wednesday. Deutsche Bank set a $38.00 price objective on shares of Pfizer and gave the stock a “buy” rating in a research note on Wednesday, October 11th. Goldman Sachs Group set a $36.00 price objective on shares of Pfizer and gave the stock a “neutral” rating in a research note on Wednesday, November 1st. Finally, BMO Capital Markets set a $39.00 price objective on shares of Pfizer and gave the stock a “buy” rating in a research note on Friday, December 15th. Two research analysts have rated the stock with a sell rating, seven have given a hold rating and twelve have issued a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average price target of $38.12.
Shares of Pfizer Inc. (NYSE PFE) traded up $1.78 during trading on Friday, reaching $39.01. 47,945,259 shares of the company’s stock were exchanged, compared to its average volume of 17,980,000. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.43 and a quick ratio of 1.15. Pfizer Inc. has a twelve month low of $30.93 and a twelve month high of $39.09. The firm has a market cap of $232,530.00, a price-to-earnings ratio of 23.93, a price-to-earnings-growth ratio of 2.30 and a beta of 1.01.
Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, October 31st. The biopharmaceutical company reported $0.67 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.65 by $0.02. The business had revenue of $13.17 billion for the quarter, compared to analyst estimates of $13.17 billion. Pfizer had a net margin of 21.70% and a return on equity of 19.13%. Pfizer’s revenue for the quarter was up .9% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.61 EPS. equities research analysts anticipate that Pfizer Inc. will post 2.6 EPS for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, March 1st. Stockholders of record on Friday, February 2nd will be issued a $0.34 dividend. This is an increase from Pfizer’s previous quarterly dividend of $0.32. This represents a $1.36 annualized dividend and a dividend yield of 3.49%. The ex-dividend date is Thursday, February 1st. Pfizer’s dividend payout ratio is 78.53%.
Pfizer announced that its board has approved a stock repurchase plan on Monday, December 18th that allows the company to repurchase $10.00 billion in outstanding shares. This repurchase authorization allows the biopharmaceutical company to purchase shares of its stock through open market purchases. Shares repurchase plans are often a sign that the company’s board of directors believes its shares are undervalued.
In other news, insider Alexander R. Mackenzie sold 14,700 shares of the company’s stock in a transaction on Wednesday, November 1st. The shares were sold at an average price of $35.30, for a total value of $518,910.00. Following the sale, the insider now directly owns 117,432 shares of the company’s stock, valued at approximately $4,145,349.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Alexander R. Mackenzie sold 6,750 shares of the company’s stock in a transaction on Friday, December 15th. The shares were sold at an average price of $37.00, for a total transaction of $249,750.00. Following the completion of the sale, the insider now directly owns 103,458 shares in the company, valued at $3,827,946. The disclosure for this sale can be found here. Insiders sold a total of 29,450 shares of company stock worth $1,065,220 over the last ninety days. Insiders own 0.06% of the company’s stock.
COPYRIGHT VIOLATION WARNING: This story was originally reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this story on another site, it was illegally copied and republished in violation of U.S. and international copyright & trademark legislation. The correct version of this story can be viewed at https://www.dispatchtribunal.com/2018/01/29/pfizer-inc-pfe-holdings-trimmed-by-general-american-investors-co-inc.html.
Pfizer Company Profile
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.